The Clinical Impact of Recent Advances in LC-MS for Cancer Biomarker Discovery and Verification

Overview

Journal Expert Rev Proteomics

Publisher Informa Healthcare

Date 2015 Nov 20

PMID 26581546

Citations 21

Authors

Hui Wang

Tujin Shi

Wei-Jun Qian

Tao Liu

Jacob Kagan

Sudhir Srivastava

Richard D Smith

Karin D Rodland

David G Camp 2nd

Affiliations

Soon will be listed here.

Abstract

Mass spectrometry (MS) -based proteomics has become an indispensable tool with broad applications in systems biology and biomedical research. With recent advances in liquid chromatography (LC) and MS instrumentation, LC-MS is making increasingly significant contributions to clinical applications, especially in the area of cancer biomarker discovery and verification. To overcome challenges associated with analyses of clinical samples (for example, a wide dynamic range of protein concentrations in bodily fluids and the need to perform high throughput and accurate quantification of candidate biomarker proteins), significant efforts have been devoted to improve the overall performance of LC-MS-based clinical proteomics platforms. Reviewed here are the recent advances in LC-MS and its applications in cancer biomarker discovery and quantification, along with the potentials, limitations and future perspectives.

Citing Articles

Crossing epigenetic frontiers: the intersection of novel histone modifications and diseases.

Yao W, Hu X, Wang X Signal Transduct Target Ther. 2024; 9(1):232.

PMID: 39278916 PMC: 11403012. DOI: 10.1038/s41392-024-01918-w.

Proteomic analyses identify HK1 and ATP5A to be overexpressed in distant metastases of lung adenocarcinomas compared to matched primary tumors.

Pasternack H, Polzer M, Gemoll T, Kumpers C, Sauer T, Lazar-Karsten P Sci Rep. 2023; 13(1):20948.

PMID: 38016997 PMC: 10684588. DOI: 10.1038/s41598-023-47767-5.

High expression of protein tyrosine phosphatase receptor S (PTPRS) is an independent prognostic marker for cholangiocarcinoma.

Lertpanprom M, Silsirivanit A, Tippayawat P, Proungvitaya T, Roytrakul S, Proungvitaya S Front Public Health. 2022; 10:835914.

PMID: 35991009 PMC: 9387352. DOI: 10.3389/fpubh.2022.835914.

Proteomic Profiling and Biomarker Discovery in Colorectal Liver Metastases.

Wong G, Diakos C, Hugh T, Molloy M Int J Mol Sci. 2022; 23(11).

PMID: 35682769 PMC: 9181741. DOI: 10.3390/ijms23116091.

High-throughput Proteomic Profiling of Male Breast Cancer Tissue.

Zografos E, Proikakis S, Anagnostopoulos A, Korakiti A, Zagouri F, Gazouli M Cancer Genomics Proteomics. 2022; 19(2):229-240.

PMID: 35181590 PMC: 8865043. DOI: 10.21873/cgp.20316.

References

Domon B, Aebersold R . Options and considerations when selecting a quantitative proteomics strategy. Nat Biotechnol. 2010; 28(7):710-21. DOI: 10.1038/nbt.1661. View

Shi T, Fillmore T, Sun X, Zhao R, Schepmoes A, Hossain M . Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum. Proc Natl Acad Sci U S A. 2012; 109(38):15395-400. PMC: 3458402. DOI: 10.1073/pnas.1204366109. View

Aebersold R, Anderson L, Caprioli R, Druker B, Hartwell L, Smith R . Perspective: a program to improve protein biomarker discovery for cancer. J Proteome Res. 2005; 4(4):1104-9. DOI: 10.1021/pr050027n. View

Zieske L . A perspective on the use of iTRAQ reagent technology for protein complex and profiling studies. J Exp Bot. 2006; 57(7):1501-8. DOI: 10.1093/jxb/erj168. View

Wiese S, Reidegeld K, Meyer H, Warscheid B . Protein labeling by iTRAQ: a new tool for quantitative mass spectrometry in proteome research. Proteomics. 2006; 7(3):340-50. DOI: 10.1002/pmic.200600422. View

Srinivas P, Verma M, Zhao Y, Srivastava S . Proteomics for cancer biomarker discovery. Clin Chem. 2002; 48(8):1160-9. View

White N, Masui O, Desouza L, Krakovska O, Metias S, Romaschin A . Quantitative proteomic analysis reveals potential diagnostic markers and pathways involved in pathogenesis of renal cell carcinoma. Oncotarget. 2014; 5(2):506-18. PMC: 3964225. DOI: 10.18632/oncotarget.1529. View

Rhein V, Song X, Wiesner A, Ittner L, Baysang G, Meier F . Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci U S A. 2009; 106(47):20057-62. PMC: 2774257. DOI: 10.1073/pnas.0905529106. View

Pepe M, Etzioni R, Feng Z, Potter J, Thompson M, Thornquist M . Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001; 93(14):1054-61. DOI: 10.1093/jnci/93.14.1054. View

10.

Kuhn E, Whiteaker J, Mani D, Jackson A, Zhao L, Pope M . Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma. Mol Cell Proteomics. 2011; 11(6):M111.013854. PMC: 3433918. DOI: 10.1074/mcp.M111.013854. View

11.

Yang Y, Huang J, Rabii B, Rabii R, Hu S . Quantitative proteomic analysis of serum proteins from oral cancer patients: comparison of two analytical methods. Int J Mol Sci. 2014; 15(8):14386-95. PMC: 4159857. DOI: 10.3390/ijms150814386. View

12.

Lipton M, Pasa-Tolic L, Anderson G, Anderson D, Auberry D, Battista J . Global analysis of the Deinococcus radiodurans proteome by using accurate mass tags. Proc Natl Acad Sci U S A. 2002; 99(17):11049-54. PMC: 129300. DOI: 10.1073/pnas.172170199. View

13.

Desouza L, Krakovska O, Darfler M, Krizman D, Romaschin A, Colgan T . mTRAQ-based quantification of potential endometrial carcinoma biomarkers from archived formalin-fixed paraffin-embedded tissues. Proteomics. 2010; 10(17):3108-16. DOI: 10.1002/pmic.201000082. View

14.

Zhu W, Smith J, Huang C . Mass spectrometry-based label-free quantitative proteomics. J Biomed Biotechnol. 2009; 2010:840518. PMC: 2775274. DOI: 10.1155/2010/840518. View

15.

Qian W, Monroe M, Liu T, Jacobs J, Anderson G, Shen Y . Quantitative proteome analysis of human plasma following in vivo lipopolysaccharide administration using 16O/18O labeling and the accurate mass and time tag approach. Mol Cell Proteomics. 2005; 4(5):700-9. PMC: 1829297. DOI: 10.1074/mcp.M500045-MCP200. View

16.

Leroy B, Rosier C, Erculisse V, Leys N, Mergeay M, Wattiez R . Differential proteomic analysis using isotope-coded protein-labeling strategies: comparison, improvements and application to simulated microgravity effect on Cupriavidus metallidurans CH34. Proteomics. 2010; 10(12):2281-91. DOI: 10.1002/pmic.200900286. View

17.

Qu Z, Meng F, Bomgarden R, Viner R, Li J, Rogers J . Proteomic quantification and site-mapping of S-nitrosylated proteins using isobaric iodoTMT reagents. J Proteome Res. 2014; 13(7):3200-11. PMC: 4084841. DOI: 10.1021/pr401179v. View

18.

Rifai N, Gillette M, Carr S . Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006; 24(8):971-83. DOI: 10.1038/nbt1235. View

19.

Bellei E, Bergamini S, Monari E, Fantoni L, Cuoghi A, Ozben T . High-abundance proteins depletion for serum proteomic analysis: concomitant removal of non-targeted proteins. Amino Acids. 2010; 40(1):145-56. DOI: 10.1007/s00726-010-0628-x. View

20.

Pawar H, Kashyap M, Sahasrabuddhe N, Renuse S, Harsha H, Kumar P . Quantitative tissue proteomics of esophageal squamous cell carcinoma for novel biomarker discovery. Cancer Biol Ther. 2011; 12(6):510-22. PMC: 3218592. DOI: 10.4161/cbt.12.6.16833. View